AR079077A1 - Derivados de piridino-piridinonas, su preparacion y su aplicacion en terapeutica de enfermedades mediadas por la tirosina quinasa - Google Patents
Derivados de piridino-piridinonas, su preparacion y su aplicacion en terapeutica de enfermedades mediadas por la tirosina quinasaInfo
- Publication number
- AR079077A1 AR079077A1 ARP100104280A ARP100104280A AR079077A1 AR 079077 A1 AR079077 A1 AR 079077A1 AR P100104280 A ARP100104280 A AR P100104280A AR P100104280 A ARP100104280 A AR P100104280A AR 079077 A1 AR079077 A1 AR 079077A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- heterocycle
- atom
- optionally substituted
- cycle
- Prior art date
Links
- 108091000080 Phosphotransferase Proteins 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 102000020233 phosphotransferase Human genes 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 8
- 229910052757 nitrogen Inorganic materials 0.000 abstract 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 5
- 125000001072 heteroaryl group Chemical group 0.000 abstract 5
- 125000005842 heteroatom Chemical group 0.000 abstract 5
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 4
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 abstract 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 239000001301 oxygen Substances 0.000 abstract 3
- 125000004429 atom Chemical group 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 108700014844 flt3 ligand Proteins 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 150000003951 lactams Chemical class 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 239000011593 sulfur Substances 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
Su preparacion y su aplicacion en terapéutica como inhibidores de la actividad quinasa de los receptores de los ligandos PDGFs y/o de los receptores del ligando FLT3. Reivindicacion 1: Un compuesto que responde a la formula (1): en la que, R1 representa un átomo de hidrogeno o un grupo alquilo C1-4; R2 representa un grupo -(CH2)n-B en donde: n' = 0, 1, 2, 3 o 4; y B representa (i) un grupo cicloalquilo C3-5 o un grupo alquilo C1-4, estando dicho grupo opcionalmente sustituido con uno o varios átomos de fluor, o (ii) un grupo alcoxi C1-4; Y, Z, V y W representan, independientemente entre si: un grupo -CH-, un átomo de carbono opcionalmente sustituido con un grupo R7, representando dicho grupo R7 un grupo alquilo C1-4 o un átomo de halogeno, un heteroátomo tal como un átomo de nitrogeno, un átomo de azufre o un átomo de oxígeno, o ningun átomo, entendiéndose que el ciclo, en el que están comprendidos V, W, Y y Z es un ciclo que comprende 5 o 6 eslabones, entendiéndose que la línea de puntos en dicho ciclo indica que el ciclo resultante es un ciclo aromático y entendiéndose que dicho ciclo comprende 0, 1 o 2 heteroátomos; representando R3 y R4, independientemente entre sí, grupos idénticos o diferentes, eligiéndose R3 y R4 entre: un átomo de hidrogeno; y un grupo alquilo C1-4 lineal; o R3 y R4 forman junto con el carbono al que están unidos un grupo cicloalquilo C3-5; m es un numero entero igual a 1, 2, 3 o 4; R5 representa un átomo de hidrogeno o un grupo alquilo C1-4; R6 representa un grupo -(CH2)n-L en el que: n = 0, 1, 2 o 3, y L es un grupo seleccionado entre los siguientes grupos: o un arilo que comprende 6 átomos de carbono; o un heteroarilo que comprende entre 5 y 6 eslabones y que comprende al menos un heteroátomo elegido entre nitrogeno, oxígeno y azufre; o un heterociclo saturado que comprende 5, 6 o 7 eslabones y que comprende al menos un heteroátomo elegido entre nitrogeno y oxígeno, siendo dicho heterociclo opcionalmente un lactamo; estando dicho grupo arilo, heteroarilo o heterociclo opcionalmente sustituido con al menos un sustituyente elegido entre (i) los grupos alquilo C1-4, lineales o ramificados, (ii) los grupos cicloalquilo C3-5, (iii) los átomos de halogeno, (iv) los arilos y (v) el bencilo; entendiéndose que, cuando L es un heteroarilo o un heterociclo, comprendiendo dicho heteroarilo o heterociclo al menos un átomo de nitrogeno, este ultimo puede estar sustituido opcionalmente con dicho sustituyente; o R5 y R6 forman juntos con el átomo de nitrogeno al que están unidos un grupo heterociclo, opcionalmente sustituido con al menos un heteroarilo, o un grupo alquilo C1-3, pudiendo estar sustituido él mismo con un heterociclo que comprende 5 o 6 átomos y comprendiendo al menos un heteroátomo elegido entre nitrogeno y oxígeno, entendiéndose que cuando se trata de un heterociclo que comprende al menos un átomo de nitrogeno, este ultimo puede estar opcionalmente sustituido; estando dicho compuesto de formula (1), sus enantiomeros y diaestereoisomeros, que comprenden sus mezclas, en forma de base o de sal de adicion a un ácido y/o en forma de solvato.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0905602A FR2952934B1 (fr) | 2009-11-23 | 2009-11-23 | Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR079077A1 true AR079077A1 (es) | 2011-12-21 |
Family
ID=42133583
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100104280A AR079077A1 (es) | 2009-11-23 | 2010-11-19 | Derivados de piridino-piridinonas, su preparacion y su aplicacion en terapeutica de enfermedades mediadas por la tirosina quinasa |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US8623893B2 (es) |
| EP (1) | EP2504338B1 (es) |
| JP (1) | JP2013511501A (es) |
| KR (1) | KR20120099732A (es) |
| CN (1) | CN102762558A (es) |
| AR (1) | AR079077A1 (es) |
| AU (1) | AU2010320692A1 (es) |
| BR (1) | BR112012012403A2 (es) |
| CA (1) | CA2781935A1 (es) |
| CL (1) | CL2012001322A1 (es) |
| CO (1) | CO6481011A2 (es) |
| CR (1) | CR20120261A (es) |
| DO (1) | DOP2012000136A (es) |
| EA (1) | EA201290383A1 (es) |
| EC (1) | ECSP12011916A (es) |
| FR (1) | FR2952934B1 (es) |
| GT (1) | GT201200154A (es) |
| IL (1) | IL219888A0 (es) |
| MA (1) | MA33819B1 (es) |
| MX (1) | MX2012005988A (es) |
| NI (1) | NI201200095A (es) |
| NZ (1) | NZ600108A (es) |
| PE (1) | PE20121338A1 (es) |
| PH (1) | PH12012501004A1 (es) |
| TN (1) | TN2012000229A1 (es) |
| TW (1) | TWI476197B (es) |
| UY (1) | UY33049A (es) |
| WO (1) | WO2011061458A1 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10420665B2 (en) | 2010-06-13 | 2019-09-24 | W. L. Gore & Associates, Inc. | Intragastric device for treating obesity |
| US9526648B2 (en) | 2010-06-13 | 2016-12-27 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| US8628554B2 (en) | 2010-06-13 | 2014-01-14 | Virender K. Sharma | Intragastric device for treating obesity |
| US10010439B2 (en) | 2010-06-13 | 2018-07-03 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| EP2524915A1 (en) | 2011-05-20 | 2012-11-21 | Sanofi | 2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors |
| HK1206257A1 (en) * | 2012-07-17 | 2016-01-08 | Sanofi | Use of vegfr-3 inhibitors for treating hepatocellular carcinoma |
| US10779980B2 (en) | 2016-04-27 | 2020-09-22 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| JP2019530678A (ja) | 2016-09-18 | 2019-10-24 | エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド | Ｙａｐ１のｏｃｔ４との相互作用を標的とするｙａｐ１阻害剤 |
| US11161851B2 (en) * | 2017-11-06 | 2021-11-02 | Suzhou Pengxu Pharmatech Co. Ltd. | Processes to produce acalabrutinib |
| KR20200104873A (ko) * | 2017-12-06 | 2020-09-04 | 린 바이오사이언스, 피티와이 엘티디. | 튜불린 억제제 |
| PE20211450A1 (es) | 2018-03-14 | 2021-08-05 | H Lee Moffitt Cancer Ct & Res | Inhibidores de yap1 que dirigen la interaccion de yap1 con oct4 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4323574B2 (ja) * | 1995-12-13 | 2009-09-02 | 大日本住友製薬株式会社 | 抗腫瘍剤 |
| US5994367A (en) * | 1997-03-07 | 1999-11-30 | The University Of North Carolina At Chapel Hill | Method for treating tumors using 2-aryl-naphthyridin-4-ones |
| JP3739916B2 (ja) * | 1997-12-02 | 2006-01-25 | 第一製薬株式会社 | サイトカイン産生阻害剤 |
| CA2447765C (en) * | 2001-05-24 | 2011-01-25 | Merck Frosst Canada & Co./Merck Frosst Canada & Cie | 1-biaryl-1,8-napthyridin-4-one phosphodiesterase-4 inhibitors |
| JO2311B1 (en) * | 2001-08-29 | 2005-09-12 | ميرك فروست كندا ليمتد | Alkyl inhibitors Ariel phosphodiesterase-4 |
| BR0316229A (pt) * | 2002-11-13 | 2005-10-04 | Chiron Corp | Métodos de tratamento de câncer e métodos relacionados |
| GB0321621D0 (en) * | 2003-09-16 | 2003-10-15 | Astrazeneca Ab | Quinazoline derivatives |
| AU2004272345A1 (en) | 2003-09-16 | 2005-03-24 | Astrazeneca Ab | Quinazoline derivatives |
| WO2005091857A2 (en) * | 2004-03-12 | 2005-10-06 | Bayer Pharmaceuticals Corporation | 1,6-naphthyridine and 1,8-naphthyridine derivatives and their use to treat diabetes and related disorders |
| WO2007113548A1 (en) * | 2006-04-06 | 2007-10-11 | Astrazeneca Ab | Naphthyridine derivatives |
| WO2007113565A1 (en) * | 2006-04-06 | 2007-10-11 | Astrazeneca Ab | Naphthyridine derivatives as anti-cancer agents |
| JP2010506879A (ja) * | 2006-10-16 | 2010-03-04 | ノバルティス アーゲー | プロテインキナーゼ阻害剤として有用なフェニルアセトアミド |
| CA2682231A1 (en) * | 2007-03-28 | 2008-10-09 | Array Biopharma Inc. | Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors |
| FR2917412B1 (fr) | 2007-06-13 | 2009-08-21 | Sanofi Aventis Sa | Derives de 7-alkynyl, 1,8-naphthyridones, leur preparation et leur application en therapeutique |
| FR2917413B1 (fr) | 2007-06-13 | 2009-08-21 | Sanofi Aventis Sa | Derives de 7-alkynyl-1,8-naphthyridones, leur preparation et leur application en therapeutique |
| FR2933700B1 (fr) | 2008-07-08 | 2010-07-30 | Sanofi Aventis | Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique |
| FR2954943B1 (fr) | 2010-01-07 | 2013-03-01 | Sanofi Aventis | Derives de pyridino-pyridinones arylsulfonamides, leur preparation et leur application en therapeutique |
| EP2524915A1 (en) * | 2011-05-20 | 2012-11-21 | Sanofi | 2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors |
-
2009
- 2009-11-23 FR FR0905602A patent/FR2952934B1/fr not_active Expired - Fee Related
-
2010
- 2010-11-19 AR ARP100104280A patent/AR079077A1/es unknown
- 2010-11-22 KR KR1020127016232A patent/KR20120099732A/ko not_active Withdrawn
- 2010-11-22 TW TW099140242A patent/TWI476197B/zh not_active IP Right Cessation
- 2010-11-22 AU AU2010320692A patent/AU2010320692A1/en not_active Abandoned
- 2010-11-22 JP JP2012539393A patent/JP2013511501A/ja active Pending
- 2010-11-22 WO PCT/FR2010/052480 patent/WO2011061458A1/fr not_active Ceased
- 2010-11-22 PH PH1/2012/501004A patent/PH12012501004A1/en unknown
- 2010-11-22 BR BR112012012403A patent/BR112012012403A2/pt not_active IP Right Cessation
- 2010-11-22 CA CA2781935A patent/CA2781935A1/fr not_active Abandoned
- 2010-11-22 MX MX2012005988A patent/MX2012005988A/es active IP Right Grant
- 2010-11-22 EP EP10799090.5A patent/EP2504338B1/fr not_active Not-in-force
- 2010-11-22 PE PE2012000710A patent/PE20121338A1/es not_active Application Discontinuation
- 2010-11-22 CN CN2010800621312A patent/CN102762558A/zh active Pending
- 2010-11-22 NZ NZ600108A patent/NZ600108A/xx not_active IP Right Cessation
- 2010-11-22 EA EA201290383A patent/EA201290383A1/ru unknown
- 2010-11-23 UY UY0001033049A patent/UY33049A/es not_active Application Discontinuation
-
2012
- 2012-05-15 DO DO2012000136A patent/DOP2012000136A/es unknown
- 2012-05-17 TN TNP2012000229A patent/TN2012000229A1/fr unknown
- 2012-05-18 GT GT201200154A patent/GT201200154A/es unknown
- 2012-05-20 IL IL219888A patent/IL219888A0/en unknown
- 2012-05-21 EC ECSP12011916 patent/ECSP12011916A/es unknown
- 2012-05-21 CR CR20120261A patent/CR20120261A/es unknown
- 2012-05-22 US US13/477,778 patent/US8623893B2/en active Active
- 2012-05-22 NI NI201200095A patent/NI201200095A/es unknown
- 2012-05-23 CL CL2012001322A patent/CL2012001322A1/es unknown
- 2012-05-23 CO CO12084563A patent/CO6481011A2/es not_active Application Discontinuation
- 2012-06-14 MA MA34962A patent/MA33819B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN102762558A (zh) | 2012-10-31 |
| BR112012012403A2 (pt) | 2017-10-10 |
| EP2504338A1 (fr) | 2012-10-03 |
| TN2012000229A1 (fr) | 2013-12-12 |
| FR2952934B1 (fr) | 2012-06-22 |
| MA33819B1 (fr) | 2012-12-03 |
| TWI476197B (zh) | 2015-03-11 |
| KR20120099732A (ko) | 2012-09-11 |
| ECSP12011916A (es) | 2012-07-31 |
| US8623893B2 (en) | 2014-01-07 |
| DOP2012000136A (es) | 2012-08-15 |
| CR20120261A (es) | 2012-07-04 |
| EP2504338B1 (fr) | 2015-03-18 |
| JP2013511501A (ja) | 2013-04-04 |
| UY33049A (es) | 2011-06-30 |
| PE20121338A1 (es) | 2012-10-15 |
| NZ600108A (en) | 2013-06-28 |
| EA201290383A1 (ru) | 2013-01-30 |
| IL219888A0 (en) | 2012-07-31 |
| FR2952934A1 (fr) | 2011-05-27 |
| US20130005724A1 (en) | 2013-01-03 |
| PH12012501004A1 (en) | 2013-01-14 |
| CO6481011A2 (es) | 2012-07-16 |
| AU2010320692A1 (en) | 2012-06-14 |
| MX2012005988A (es) | 2012-09-07 |
| CL2012001322A1 (es) | 2012-08-17 |
| TW201121971A (en) | 2011-07-01 |
| CA2781935A1 (fr) | 2011-05-26 |
| NI201200095A (es) | 2012-08-20 |
| WO2011061458A1 (fr) | 2011-05-26 |
| GT201200154A (es) | 2013-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR079077A1 (es) | Derivados de piridino-piridinonas, su preparacion y su aplicacion en terapeutica de enfermedades mediadas por la tirosina quinasa | |
| AR072798A1 (es) | Derivados de pirido-piridinonas, su preparacion, composicion farmaceutica y su uso en el tratamiento de las enfermedades ligadas a la actividad de la proteina quinasa | |
| AR099913A1 (es) | Derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| DOP2010000227A (es) | Derivados biciclicos de carboxamidas aza-biciclicas, su preparacion y su aplicacion terapeutica | |
| NI201000124A (es) | Derivados de carboxamidas azabicíclicas, su preparación y su aplicación en terapéutica | |
| AR087328A1 (es) | Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak | |
| AR096979A1 (es) | Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR103138A1 (es) | Compuestos de heteroarilo como inhibidores de la irak y usos de los mismos | |
| AR066107A1 (es) | Derivados de triazolopiridin - carboxamidas y triazolopirimidin-carboxamidas, su preparacion y su aplicacion en terapeutica como inhibidores de la enzimamonoacil glicerol lipasa y composiciones qu los contienen. | |
| AR076435A1 (es) | Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos | |
| AR060658A1 (es) | Derivados de diceto-piperazina y piperidina como agentes antivirales | |
| ES2684517T3 (es) | Compuestos de heterociclilo como inhibidores de MEK | |
| CO6220878A2 (es) | Composicion herbicida que comprende un derivado de isoxazolina o una sal del mismo | |
| AR068538A1 (es) | Compuesto heterociclico de 5 miembros con actividad supresora de la secrecion de acido | |
| AR073565A1 (es) | Derivados de bencimidazol, procesos de preparacion y composiciones farmaceuticas que los contienen | |
| AR063988A1 (es) | Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| AR048974A1 (es) | Derivados sustituidos del dioxido de oxazol-benzoisotiazol y composiciones farmaceuticas. | |
| CO6150150A2 (es) | Derivados de 7-alquinil-1,8-naftiridonas su prepacion y su aplicacion en terapeutica | |
| AR092313A1 (es) | Compuestos heterobiciclicos n-sustituidos y derivados para combatir plagas de animales ii | |
| UY32801A (es) | Nuevos derivados dihidroindolonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR110240A1 (es) | Compuestos de diaminotriazina | |
| AR096040A1 (es) | Compuestos sustituidos y condensados de pirimidina como inhibidores de pde4b | |
| AR072200A1 (es) | Derivados dibenzotiazepina y usos de los mismos | |
| AR097795A1 (es) | Derivados de n-arilmetilo sulfonamida como moduladores negativos de nr2a | |
| AR072486A1 (es) | Derivados de benzotiadiazinas cicloalquiladas su procedimiento de preparacion y las composiciones farmaceuticas que los contienen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |